Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-Bradykinin

@article{Molinaro2002AngiotensinConvertingEI,
  title={Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-Bradykinin},
  author={Giuseppe Molinaro and Massimo Cugno and M{\'e}lissa Perez and Yves Lepage and Nicole Gervais and Angelo Agostoni and Albert Adam},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2002},
  volume={303},
  pages={232 - 237}
}
  • G. Molinaro, M. Cugno, A. Adam
  • Published 1 October 2002
  • Biology, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
Angioedema (AE) is a rare but potentially life-threatening side effect of therapy with inhibitors of angiotensin-converting enzyme (ACE), the main bradykinin (BK)- inactivating metallopeptidase in humans. The pathogenesis of ACE inhibitor (ACEi)- associated AE (AE+) is presently unknown, although there is increasing evidence of a kinin role. We analyzed the metabolism of endogenous BK (B2 receptor agonist) and its active metabolite, des-Arg9-BK (B1 receptor agonist), in the presence of an ACEi… 

Figures and Tables from this paper

Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors
TLDR
It has been observed that patients previously stable under ACE inhibitor will most likely develop AE soon after the addition of another medication, including the combination of aspirin or non-steroid anti-inflammatory drugs with ACE inhibitor which has proved to be the most common cause, accounting for close to 50% of all AE cases.
Angioedema induced by angiotensin-converting enzyme inhibitors
TLDR
The present review will focus on current and relevant aspects of ACEI-induced angioedema, including the pathological mechanism, epidemiology and risk factors, differential diagnosis, patient management and treatment.
Renin-angiotensin system inhibitors and angioedema: anesthetic implications.
TLDR
Trauma of the airway, especially during difficult intubation, may precipitate severe angioedema and lifetime discontinuation of all renin-angiotensin inhibitors may be warranted.
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
TLDR
This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of angiotensin-converting enzyme inhibitor–associated angioedema, and found that it was true.
Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors.
TLDR
The complexity of HSR in hemodialysis is highlighted, suggesting, as with angioedema, that these rare, but life-threatening adverse events are governed by several metabolic and genetic factors.
Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema.
TLDR
The data suggest that polymorphism of ACE I/D and the bradykinin B2 receptor polymorphisms are not involved in the development of ACEi-induced angio-oedema when considered individually.
[Drug-induced angioedema : Focus on bradykinin].
TLDR
When angioedema arises within the context of concomitant ACE inhibitor use, additive bradykinin degradation effects may be implicated and the suspected cause also relates to the degradation of brady Kinin.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema
TLDR
DPPIV activity is depressed in individuals with hypertension during acute ACEI-associated angioedema, and there was no effect of acute ACE inhibition or corticosteroids on DPPiv activity.
Plasma bradykinin in angio-oedema
Biochemical Basis of Angioedema Associated With Recombinant Tissue Plasminogen Activator Treatment: An In Vitro Experimental Approach
TLDR
It is concluded that rtPA used in vitro at a therapeutic concentration has the capacity to generate significant quantities of kinins from human plasma, and depends on the activation of the fibrinolytic pathway.
Novel Mode of Action of Angiotensin I Converting Enzyme Inhibitors
TLDR
B1 receptor activation by ACE inhibitors, a novel mode of action reported here first, can contribute to their therapeutic effects by releasing NO in the heart and to some side effects.
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.
TLDR
A 4-day trial of withdrawal of the ACE inhibitor or temporary substitution of another class of antihypertensive agent inexpensively and easily ascertains if the ACE inhibitors caused the cough is easily ascertained.
Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma.
  • M. Cyr, Y. Lepage, A. Adam
  • Biology, Medicine
    American journal of physiology. Heart and circulatory physiology
  • 2001
TLDR
A mathematical model applied to the BK kinetically released from endogenous high-molecular-weight kininogen during plasma activation in the presence of an ACE inhibitor revealed a significant difference in the rate of formation of BK between men and women, forming a basis for future pathophysiological studies of inflammatory processes where activation of the contact system of plasma and the kinins is involved.
Atypical reactions associated with use of angiotensin‐converting enzyme inhibitors and apheresis
TLDR
Patients receiving ACE inhibitor therapy who are undergoing therapeutic plasma exchange with albumin replacement solutions are at high risk for atypical reactions and it is recommended that ACE inhibitors be withheld for at least 24 hours before that procedure.
Metabolism of Bradykinin by Peptidases in Health and Disease
...
1
2
3
4
...